NeoPath receives notice of allowance for new U.S. patent.REDMOND, Wash.--(BUSINESS WIRE)--Sept. 25, 1996--NeoPath, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on :NPTH NPTH Non-Plated Through-Hole (PCB (printed circuit board manufacturing) ) today announced that the U.S. Patent and Trademark Office has allowed and will grant the Company a U.S. Patent on an application entitled, "Imaging System Transfer Function Control Method and Apparatus." The patent will be applicable to a broad range of image interpretation products. The invention is currently used for accurately measuring and controlling the imaging performance of the AutoPap 300 QC System, the Company's automated device for rescreening microscopic images from Pap smear Pap smear or Papanicolaou smear Sample of cells from the vagina and cervix of the uterus for laboratory staining and examination to detect genital herpes and early-stage cancer, especially of the cervix. Developed by the Greek-born U.S. slides. The Pap test Pap test, Pap smear, or Papanicolaou test (păp'ənē`kəlou), medical procedure used to detect cancer of the uterine cervix. is a screening procedure that can reveal abnormalities in cervical cells that indicate a precancerous precancerous /pre·can·cer·ous/ (-kan´ser-us) pertaining to a pathologic process that tends to become malignant. pre·can·cer·ous adj. or cancerous condition. High-speed video microscopes and cameras in NeoPath's AutoPap System focus, capture and digitize high-quality, diagnostically relevant images from the nonuniform distributions of cells on a conventional Pap smear slide. Based on those images, the System automatically analyzes and extracts important features of cellular material, and classifies a specimen. The new invention New Invention may refer to:
"This invention is one of the most significant technical advancements NeoPath has made to date," said Alan C. Nelson, Ph.D., president and chief executive officer of NeoPath, Inc. "Because the performance of the AutoPap imaging system is assured, the AutoPap System can achieve the very high levels of automation and accuracy that is so critical to clinical laboratories in their Pap smear rescreening." Pap smear testing is used widely throughout the developed world for early detection of cervical cancer Cervical Cancer Definition Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably, forming tumors. , the second most common cancer among women with approximately 500,000 new cases reported each year. Cervical cancer is nearly 100% curable cur·a·ble adj. Capable of being cured or healed. if detected and treated at an early stage. Despite the acknowledged success of the Pap smear test, there are certain limitations in the current method of human Pap smear review. Abnormal Pap smears may be misclassified as normal, giving a "false negative" result. The AutoPap System utilizes proprietary image-processing computers to identify those Pap smears with the highest potential for abnormality. To date, NeoPath has been issued five U.S. patents, and has received notices of allowance for three U.S. patents covering its fundamental technologies; the Company has 32 additional U.S. patents pending. NeoPath's core expertise is in the research, development, and commercialization of technologies to automate the interpretation of medical images. The Company, which is based in Redmond, Washington, has approximately 175 employees. Forward-looking statements in this release are made pursuant to the safe harbor Safe Harbor 1. A legal provision to reduce or eliminate liability as long as good faith is demonstrated. 2. A form of shark repellent implemented by a target company acquiring a business that is so poorly regulated that the target itself is less attractive. provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. These forward-looking statements are subject to certain risks and uncertainties, including without limitation, product and manufacturing regulatory approvals; the Company's limited manufacturing, marketing, customer service and support capabilities; the Company's sole or limited source of supply of certain components; the status of competing products; and other risks and uncertainties detailed in the Company's filings with the Securities and Exchange Commission. CONTACT: NeoPath, Inc. Kekst and Company Stacie Byars or Todd Fogarty (206) 556-3050 (212) 593-2655 |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion